R & D

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line reatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma

This information is intended to notify the press release issued on January 4 by Bristol Myers Squibb. Please click https://www.bms.com/media/press-releases.html for the original press release.